Á¦¾à ¹× ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Çüź°, ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Activated Carbon For Pharma & Healthcare Market Size, Share & Trends Analysis Report By Form (Powdered, Granular), By Application (API Production, Finished Drug Production), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1751223
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 132 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 6¾ï 5,210¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2030³âÀÇ CAGRÀº 6.3%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. Á¦¾à ¹× ÀÇ·á ºÐ¾ß¿¡¼ Ȱ¼ºÅº¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× ÁÖ¿ä ÀÌÀ¯´Â ¿À¿°¹°ÁúÀ» Á¤ÈÇϰí ÈíÂøÇÏ´Â ´É·ÂÀÌ ¶Ù¾î³ª±â ¶§¹®ÀÔ´Ï´Ù. º´¿ø¿¡¼´Â ±ú²ýÇÑ °ø±â¿Í ¹°À» À¯ÁöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÀǾàǰ Á¦Á¶¿¡¼´Â ÀǾàǰ¿¡¼ ºÒ¼ø¹°°ú ºÒÇÊ¿äÇÑ »ö¼Ò¸¦ Á¦°ÅÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÎü¿¡ »ç¿ëÀÌ Çã°¡µÈ ÀÇ·á¿ë Ȱ¼ºÅºÀº ÀÀ±ÞÀÇ·á¿¡¼ µ¶±Ø¹° Áßµ¶À» Ä¡·áÇÏ´Â Áß¿äÇÑ ÅøÀ̱⵵ ÇÕ´Ï´Ù. Ȱ¼ºÅºÀº ¼ÒȰü ³»¿¡¼ µ¶¼Ò¿Í °áÇÕÇÏ¿© µ¶¼ÒÀÇ Ã¼³» Èí¼ö¸¦ Â÷´ÜÇÕ´Ï´Ù.
¸Å³â ÀÔ¿ø ȯÀÚÀÇ ¾à 5%¿¡¼ 10%¿¡ ÇØ´çÇÏ´Â ¾à 170¸¸ ¸íÀÇ È¯ÀÚ°¡ HAI¿¡ °É¸®¸ç, ÀÌ·Î ÀÎÇØ ¾à 10¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¼öÄ¡´Â ´Ù¸¥ ¸¹Àº ÁÖ¿ä Áúº´ÀÇ ¿µÇâÀ» ´É°¡ÇÏ´Â ½É°¢ÇÑ °øÁß º¸°Ç ¹®Á¦¸¦ °Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ÀÇ·á ½Ã¼³Àº ÷´Ü Á¤È ±â¼ú¿¡ ÁÖ¸ñÇϰí ÀÖÀ¸¸ç, ±× Áß¿¡¼µµ Ȱ¼ºÅºÀº À¯ÇØÇÑ ÀÔÀÚ¿Í º´¿ø±ÕÀ» È¿À²ÀûÀ¸·Î °É·¯³¾ ¼ö ÀÖÀ¸¹Ç·Î °¡Àå À¯·ÂÇÑ È帷Π¶°¿À¸£°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ È°¼ºÅºÀº ³ôÀº ´Ù°ø¼º°ú ¿ì¼öÇÑ ÈíÂø ´É·ÂÀ¸·Î ÀÎÇØ Á¦¾à »ê¾÷¿¡¼ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ ÀǾàǰ Á¦Á¶½Ã ¿À¿°¹°Áú, ¾È·á, ÀÜ·ù¹°À» È¿°úÀûÀ¸·Î Á¦°ÅÇÏ¿© ÃÖÁ¾ Á¦Ç°ÀÇ Ç°Áú°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
Á¦¾à ¹× ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå ÇÏÀ̶óÀÌÆ®
- Çüź°·Î´Â ºÐ¸» ÇüŰ¡ 2024³â 56.3%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾Ç.
- Á¦¾à ¹× ÇコÄɾî¿ë °ú¸³Çü Ȱ¼ºÅº ½ÃÀåÀº ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
- Èí¼ö¼ºÀÌ ¶Ù¾î³ª°í, Ãë±Þ ¹× º¸°üÀÌ ¿ëÀÌÇϸç, ¹Ýº¹ÀûÀÎ ¿©°ú »çÀÌŬÀ» °ßµô ¼ö ÀÖ´Ù´Â Á¡ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
- ¿ëµµº°·Î´Â ¿ø·áÀǾàǰ Á¦Á¶°¡ Á¦¾à ¹× ÇコÄÉ¾î »ê¾÷ÀÇ È°¼ºÅº ½ÃÀåÀ» ÁÖµµÇϸç 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- ¿ÏÁ¦ÀǾàǰ Á¦Á¶ ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß CAGR 6.2%·Î Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2024³â 48.6%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- ¾Æ½Ã¾Æ ±¹°¡µéÀÇ ÀǾàǰ Á¦Á¶ Áõ°¡·Î ÀÎÇØ Á¦Á¶½Ã º¸´Ù È¿À²ÀûÀÎ Á¤Á¦ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå °³¿ä
Á¦3Àå Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ¸ð½ÃÀå Àü¸Á
- °ü·Ã ½ÃÀå Àü¸Á
- ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¾÷°èÀÇ °úÁ¦
- ¾÷°èÀÇ ±âȸ
- ¾÷°è ºÐ¼® Åø
- Porter's Five Forces ºÐ¼®
- °Å½Ãȯ°æ ºÐ¼®
Á¦4Àå Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå : ÇüÅ ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå : ÇüÅ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- ºÐ¸»
- ÀÔ»ó
- ±âŸ ÇüÅÂ
Á¦5Àå Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- API Á¦Á¶
- Á¦¾à¡¤ÇコÄÉ¾î ½ÃÀå ¸ÅÃâ Ãß»ê°ú ¿¹Ãø(API Á¦Á¶ ºÐ¾ß, 2018-2030³â)
- ¿ÏÁ¦ÀǾàǰ »ý»ê
- Á¦¾à¡¤ÇコÄÉ¾î ½ÃÀå ¸ÅÃâ Ãß»ê°ú ¿¹Ãø(¿Ï¼º ÀǾàǰ »ý»ê, 2018-2030³â)
- ±âŸ
- Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå ¸ÅÃâ Ãß»ê°ú ¿¹Ãø(±âŸ ¿ëµµ), 2018-2030³â
Á¦6Àå Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
Á¦7Àå Á¦¾à¡¤ÇコÄɾî¿ë Ȱ¼ºÅº ½ÃÀå - °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷ ºÐ·ù
- ±â¾÷ È÷Æ®¸Ê
- Æ÷Áö¼Ç ºÐ¼®, 2024³â
- Àü·« ÁöµµÁ¦ÀÛ
- È®´ë
- ÇÕº´°ú Àμö
- ÆÄÆ®³Ê½Ê°ú Çù¾÷
- »õ·Î¿î Æû ¸±¸®½º
- ¿¬±¸°³¹ß
- ±â¾÷ °³¿ä
- Jacobi Group
- Chemviron(a Kuraray Company)
- Haycarb PLC
- Boyce Carbon
- Southern Carbon Pvt. Ltd.
- Suneeta Carbons
- Calgon Carbon Corporation
- Karbonous Inc.
- Norit
- Donau Carbon GmbH
KSA
¿µ¹® ¸ñÂ÷
Activated Carbon For Pharma & Healthcare Market Growth & Trends:
The global activated carbon for pharma & healthcare market size is anticipated to reach USD 652.1 million by 2030 and is expected to grow at a CAGR of 6.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for activated carbon in the pharmaceutical and healthcare sectors continues to grow, largely due to its exceptional ability to purify and adsorb contaminants. In hospitals, it plays a vital role in maintaining clean air and water, while in pharmaceutical manufacturing, it's used to remove impurities and unwanted colorants from medications. Medical-grade activated carbon, approved for human use, is also a critical tool in emergency medicine for treating poisonings. It works by binding to toxins in the gastrointestinal tract, stopping them from being absorbed into the body, a life-saving measure in cases of overdose or accidental ingestion.
This rising demand is also tied to the significant challenge posed by hospital-acquired infections (HAIs) in the U.S. Each year, approximately 1.7 million patients, roughly 5% to 10% of those hospitalized, develop an HAI, with close to 100,000 resulting deaths. These numbers highlight a serious public health concern that exceeds the impact of many other major diseases. To combat this, healthcare facilities are turning to advanced purification technologies, with activated carbon being a top choice due to its efficiency in filtering harmful particles and pathogens.
In addition, activated carbon is heavily utilized in the pharmaceutical industry for its high porosity and excellent adsorption capabilities, which are enhanced through thermal processing. These properties allow it to effectively remove contaminants, pigments, and residues during drug production, improving the final product's quality and safety.
Activated Carbon For Pharma & Healthcare Market Highlights
- Based on form, the powdered form dominated the market with the largest revenue share of 56.3% in 2024.
- The granular activated carbon market for the pharmaceutical and healthcare industry is estimated to grow at the fastest CAGR over the forecast period.
- Its superior absorption, easy handling, storage, and ability to withstand repeated filtration cycles drive the growth.
- Based on application, API production led the activated carbon market for the pharma & healthcare industry, accounting for the largest revenue share in 2024.
- The finished drug production segment is expected to grow at a significant CAGR of 6.2% over the forecast period.
- Asia Pacific dominated the global market with the largest revenue share of 48.6% in 2024.
- The rise in pharmaceutical production across Asian countries fueled the demand for more efficient purification methods during production.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources & Third-Party Perspectives
- 1.3.4. Primary Research
- 1.4. Information Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Data Visualization
- 1.6. Data Validation & Publishing
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Activated Carbon For Pharma & Healthcare Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related Market Outlook
- 3.2. Industry Value Chain Analysis
- 3.3. Regulatory Framework
- 3.4. Market Dynamics
- 3.4.1. Market Driver Analysis
- 3.4.2. Market Restraint Analysis
- 3.4.3. Industry Challenges
- 3.4.4. Industry Opportunities
- 3.5. Industry Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. Macro-environmental Analysis
Chapter 4. Activated Carbon For Pharma & Healthcare Market: Form Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Activated Carbon For Pharma & Healthcare Market: Form Movement Analysis & Market Share, 2024 & 2030
- 4.3. Powdered
- 4.3.1. Powdered Form Market Revenue Estimates and Forecasts, 2018 - 2030 (Kilotons, USD Million)
- 4.4. Granular
- 4.4.1. Granular Form Market Revenue Estimates and Forecasts, 2018 - 2030 (Kilotons, USD Million)
- 4.5. Other Form
- 4.5.1. Other Form Market Revenue Estimates and Forecasts, 2018 - 2030 (Kilotons, USD Million)
Chapter 5. Activated Carbon For Pharma & Healthcare Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Activated Carbon For Pharma & Healthcare Market: Application Movement Analysis & Market Share, 2024 & 2030
- 5.3. API Production
- 5.3.1. Activated Carbon For Pharma & Healthcare Market Revenue Estimates and Forecasts, in API Production, 2018 - 2030 (Kilotons, USD Million)
- 5.4. Finished Drug Production
- 5.4.1. Activated Carbon For Pharma & Healthcare Market Revenue Estimates and Forecasts, in Finished Drug Production, 2018 - 2030 (Kilotons, USD Million)
- 5.5. Others
- 5.5.1. Activated Carbon For Pharma & Healthcare Market Revenue Estimates and Forecasts, in Other Applications, 2018 - 2030 (Kilotons, USD Million)
Chapter 6. Activated Carbon For Pharma & Healthcare Market: Regional Estimates & Trend Analysis
- 6.1. Regional Movement Analysis & Market Share, 2024 & 2030
- 6.2. North America
- 6.2.1. North America activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.2.2. U.S.
- 6.2.2.1. Key country dynamics
- 6.2.2.2. U.S. activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.2.3. Canada
- 6.2.3.1. Key country dynamics
- 6.2.3.2. Canada activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.2.4. Mexico
- 6.2.4.1. Key country dynamics
- 6.2.4.2. Mexico activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3. Europe
- 6.3.1. Europe activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3.2. Germany
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Germany activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3.3. UK
- 6.3.3.1. Key country dynamics
- 6.3.3.2. UK activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3.4. France
- 6.3.4.1. Key country dynamics
- 6.3.4.2. France activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3.5. Italy
- 6.3.5.1. Key country dynamics
- 6.3.5.2. Italy activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.3.6. Spain
- 6.3.6.1. Key country dynamics
- 6.3.6.2. Spain activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4. Asia Pacific
- 6.4.1. Asia Pacific activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4.2. China
- 6.4.2.1. Key country dynamics
- 6.4.2.2. China activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4.3. India
- 6.4.3.1. Key country dynamics
- 6.4.3.2. India activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4.4. Japan
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Japan activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4.5. South Korea
- 6.4.5.1. Key country dynamics
- 6.4.5.2. South Korea activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.4.6. Australia
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Australia activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.5. Latin America
- 6.5.1. Latin America activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.5.2. Brazil
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Brazil activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.5.3. Argentina
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Argentina activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.6. Middle East & Africa
- 6.6.1. Middle East & Africa activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.6.2. South Africa
- 6.6.2.1. Key country dynamics
- 6.6.2.2. South Africa activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
- 6.6.3. Saudi Arabia
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Saudi Arabia activated carbon for pharma & healthcare market estimates & forecast, 2018 - 2030 (Kilotons, USD Million)
Chapter 7. Activated Carbon For Pharma & Healthcare Market - Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company Categorization
- 7.3. Company Heat Map
- 7.4. Position Analysis, 2024
- 7.5. Strategy Mapping
- 7.5.1. Expansion
- 7.5.2. Mergers & Acquisition
- 7.5.3. Partnerships & Collaborations
- 7.5.4. New Form Launches
- 7.5.5. Research And Development
- 7.6. Company Profiles
- 7.6.1. Jacobi Group
- 7.6.1.1. Participant's overview
- 7.6.1.2. Financial performance
- 7.6.1.3. Form benchmarking
- 7.6.1.4. Recent developments
- 7.6.2. Chemviron (a Kuraray Company)
- 7.6.2.1. Participant's overview
- 7.6.2.2. Financial performance
- 7.6.2.3. Form benchmarking
- 7.6.2.4. Recent developments
- 7.6.3. Haycarb PLC
- 7.6.3.1. Participant's overview
- 7.6.3.2. Financial performance
- 7.6.3.3. Form benchmarking
- 7.6.3.4. Recent developments
- 7.6.4. Boyce Carbon
- 7.6.4.1. Participant's overview
- 7.6.4.2. Financial performance
- 7.6.4.3. Form benchmarking
- 7.6.4.4. Recent developments
- 7.6.5. Southern Carbon Pvt. Ltd.
- 7.6.5.1. Participant's overview
- 7.6.5.2. Financial performance
- 7.6.5.3. Form benchmarking
- 7.6.5.4. Recent developments
- 7.6.6. Suneeta Carbons
- 7.6.6.1. Participant's overview
- 7.6.6.2. Financial performance
- 7.6.6.3. Form benchmarking
- 7.6.6.4. Recent developments
- 7.6.7. Calgon Carbon Corporation
- 7.6.7.1. Participant's overview
- 7.6.7.2. Financial performance
- 7.6.7.3. Form benchmarking
- 7.6.7.4. Recent developments
- 7.6.8. Karbonous Inc.
- 7.6.8.1. Participant's overview
- 7.6.8.2. Financial performance
- 7.6.8.3. Form benchmarking
- 7.6.8.4. Recent developments
- 7.6.9. Norit
- 7.6.9.1. Participant's overview
- 7.6.9.2. Financial performance
- 7.6.9.3. Form benchmarking
- 7.6.9.4. Recent developments
- 7.6.10. Donau Carbon GmbH
- 7.6.10.1. Participant's overview
- 7.6.10.2. Financial performance
- 7.6.10.3. Form benchmarking
- 7.6.10.4. Recent developments